TAMS: Topical Azithromycin Meibomian Gland Dysfunction Survey

• Research type

  Research Study

• Full title

  TAMS: Topical Azithromycin Meibomian Gland Dysfunction Survey

• IRAS ID

  269433

• Contact name

  Ian Jarvis

• Contact email

  ianjarvis2@nhs.net

• Sponsor organisation

  Tayside Health Board

• Duration of Study in the UK

  0 years, 7 months, 1 days

• Research summary

  1. Introduction
  Meibomian gland dysfunction is caused by chronic inflammation of the Meibomian glands which affects the quality of secretion from those glands. This results in rapid evaporation of the tear film leading to symptoms of dry eye. Current treatment regimens mainly address only the symptoms and not the underlying cause of dry eye.

  2 BACKGROUND & RATIONALE

  Meibomian gland dysfunction can have a significant impact on patient lifestyle. There are many documented strategies for treating MGD, however there are not many papers in the literature with regard to topical azithromycin.It has been shown that the effect of topical azythythromycin on Meibomina Gland Dysfunction was as effective as oral doxycycline and in some areas better. With oral doxycycline, antibiotic allergy is often a problem. Other possible effects such as GI upset >1/10and UV sensitivity 1/100-1/100(3)are often encountered. However there are no recorded issues with topical azithromycn. Also, the course is much shorter, one month compared to three months for oral doxycycline. This helps with compliance and the likelihood of completing the course of treatment.

  This study hopes to show that topical azithromycin has a lasting impact on patient symptoms and management of Meibomian gland dysfunction.

  3 STUDY OBJECTIVES & OUTCOMES
  To assess the impact of treatment on patient symptoms and management of MGD by analysis of a post treatment survey. A reduction in symptoms and reduced management regime will be a measure of the success of the treatment. Also, collation of clinical signs will be analysed to look for any statistically significant change post-treatment

• REC name

  Wales REC 7

• REC reference

  19/WA/0257

• Date of REC Opinion

  1 Oct 2019

• REC opinion

  Further Information Favourable Opinion